Revolution Medicines, Inc. (RVMD) Secures Positive CHMP Opinion for RASONQUE in Metastatic PDAC

Revolution Medicines (RVMD) announced the EMA's Committee for Medicinal Products for Human Use issued a positive opinion for RASONQUE as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma. The recommendation is based on Phase 3 trial results showing RASONQUE improved overall survival (13.2 months vs. 6.7 months with chemotherapy) and progression-free survival (7.2 months vs. 3.6 months). The EMA's expedited review process was used.

Revolution Medicines' (RVMD) RASONQUE showed a 60% reduction in death risk vs. chemotherapy in a Phase 3 trial for pancreatic cancer. The EMA's CHMP gave a positive opinion for its use in the EU. The drug is already FDA-approved in the U.S.

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

Revolution Medicines (RVMD) shares fell after FDA review documents questioned the objective response rate of its drug candidate Rasonque. RBC Capital Markets maintains an Outperform rating with a $259 price target, citing overall survival data. The company has no revenue, a P/S ratio of 72.9x, and a GF Score of 27/100, indicating challenges in profitability and growth.

Truist recommends buying Revolution Medicines (RVMD) shares after a selloff, attributing the drop to FDA review data showing stronger activity in KRAS G12V than G12D. The firm notes G12D efficacy remains clinically meaningful and maintains a Buy rating with a $240 price target. Other analysts have also recently raised price targets for RVMD.

Revolution Medicines' stock fell 7.1% after FDA concerns about RASONQUE's efficacy across KRAS mutation subtypes. RBC raised its price target to $259, but insider selling and market downturns added pressure. The stock hit an intraday low of $180.52, trading well above its 200-day average.